Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Central and branch retinal vein occlusions are major causes of visual loss. Hemorrhage and
capillary nonperfusion, when they involve the macula, can contribute to visual loss, but the
major cause is macular edema. Focal and grid laser photocoagulation can sometimes provide
benefit in patients with macular edema due to branch vein occlusions, but several laser
treatments are often needed and recovery of vision can be very slow and incomplete 1. Laser
photocoagulation does not provide benefit for macular edema due to central vein occlusions 2.
Therefore, new treatments are needed.The objective of this study is to assess the bioactivity
of 3 intravitreous injections 0.5 mg or 0.3 mg of ranibizumab in patients with macular edema
due to central and branch retinal vein occlusions and correlate activity with peak and trough
aqueous levels. The purpose of this research protocol is pilot study to determine if a
randomized placebo controlled trial is warranted.